Paxman AB (PAX) - Total Assets
Based on the latest financial reports, Paxman AB (PAX) holds total assets worth Skr487.65 Million SEK (≈ $52.48 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Paxman AB - Total Assets Trend (2016–2024)
This chart illustrates how Paxman AB's total assets have evolved over time, based on quarterly financial data. Also see PAX market cap overview for the company's overall valuation and market capitalisation.
Paxman AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Paxman AB's total assets of Skr487.65 Million consist of 57.3% current assets and 42.7% non-current assets. Review PAX current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 17.7% |
| Accounts Receivable | Skr46.57 Million | 20.5% |
| Inventory | Skr29.69 Million | 13.1% |
| Property, Plant & Equipment | Skr45.21 Million | 19.9% |
| Intangible Assets | Skr38.93 Million | 17.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Paxman AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Paxman AB stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Paxman AB's current assets represent 57.3% of total assets in 2024, a decrease from 98.8% in 2016.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2024, up from 2.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 20.5% of total assets.
Paxman AB Competitors by Total Assets
Key competitors of Paxman AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Stratec SE
XETRA:SBS
|
Germany | €408.98 Million |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
DRTECH Corporation
KQ:214680
|
Korea | ₩235.84 Billion |
|
Novacyt
PA:ALNOV
|
France | €40.28 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
Paxman AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.68 | 2.42 | 0.60 |
| Quick Ratio | 4.07 | 1.90 | 0.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr184.76 Million | Skr69.72 Million | Skr-19.73 Million |
Paxman AB - Advanced Valuation Insights
This section examines the relationship between Paxman AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 36.0% |
| Total Assets | Skr227.23 Million |
| Market Capitalization | $147.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Paxman AB's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Paxman AB's assets grew by 36.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Paxman AB (2016–2024)
The table below shows the annual total assets of Paxman AB from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr227.23 Million ≈ $24.45 Million |
+35.97% |
| 2023-12-31 | Skr167.12 Million ≈ $17.99 Million |
-3.93% |
| 2022-12-31 | Skr173.96 Million ≈ $18.72 Million |
+4.58% |
| 2021-12-31 | Skr166.34 Million ≈ $17.90 Million |
+116.00% |
| 2020-12-31 | Skr77.01 Million ≈ $8.29 Million |
-9.37% |
| 2019-12-31 | Skr84.97 Million ≈ $9.14 Million |
+52.45% |
| 2018-12-31 | Skr55.74 Million ≈ $6.00 Million |
+22.22% |
| 2017-12-31 | Skr45.61 Million ≈ $4.91 Million |
+107.34% |
| 2016-12-31 | Skr22.00 Million ≈ $2.37 Million |
-- |
About Paxman AB
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment worldwide. It serves various cancer centers and hospitals. The company has collaborated with the University of Huddersfield and the University of Leeds to develop a wearable medical cooling device; and the National University Hospital of … Read more